Philippines explains requirements for product information changes
This article was originally published in SRA
The Philippine Food and Drug Administration has issued a circular clarifying the requirements that pharmaceutical companies need to fulfil when requesting changes/revisions to their products' product information (ie package inserts, labels, patient information leaflets, etc)1.
You may also be interested in...
The European Medicines Agency may decide this week on a dozen requests by companies seeking new uses of their approved drugs.
Regulators in the EU have decided on specific arrangements they plan to employ if sponsors detect and report nitrosamine impurities in their products being sold on the market.
The European Medicines Agency is exploring the feasibility and utility of contacting patients’ organizations for their input as soon as its medicines evaluation committee starts reviewing a new drug.